2024 World Conference on Lung Cancer (WCLC) - Posters-P2.17A.05 Racial and Gender Disparities in Immune-Related Adverse Effects: A Nationwide Inpatient Sample Database Analysis

P2.17A.05 Racial and Gender Disparities in Immune-Related Adverse Effects: A Nationwide Inpatient Sample Database Analysis

Back to course

Pdf Summary

The study, presented by Kanishka Uttam Chandani, MD, and colleagues, analyzes racial and gender disparities in immune-related adverse effects (irAEs) among cancer patients receiving immune checkpoint inhibitors (ICIs). Utilizing data from the National Inpatient Sample (NIS) database from 2016 to 2020, the research examines 25,814 patients to evaluate the associations between irAEs and demographic factors, such as race and gender.<br /><br />The findings reveal a distinct pattern across different racial and gender groups. In the cohort, 58.58% were male and 41.41% female. Regarding racial composition, 63.9% were White, 7.12% African American, 12.43% Hispanic, 4.37% Asian/Pacific Islander, 0.42% Native American, and 11.72% identified as other races. The study highlights that 10.38% of all patients experienced irAEs, with Native Americans (14.3%) and Asian/Pacific Islander individuals (12%) having the highest prevalence, followed by African Americans (11.9%) and Whites (11%).<br /><br />An analysis of socioeconomic backgrounds shows that a significant portion of African American patients belonged to the lowest income quartile, whereas Asian/Pacific Islander patients predominantly fell into the highest income quartile. Insurance coverage varied, with 51.7% of White patients having commercial/private health insurance, compared to 37.4% of African Americans and 39.1% of Hispanics relying on Medicaid.<br /><br />Notably, Hispanic patients had a lower adjusted odds ratio (aOR) for irAEs compared to White patients (aOR 0.61), while females had a higher likelihood of irAEs than males (aOR 1.27). These disparities underscore the importance of considering demographic factors to enhance equitable healthcare and inform risk assessment for irAEs in patients undergoing cancer treatment with ICIs. The study concludes that more research is needed to identify predictive biomarkers for irAEs and further explore the demographic influences observed.

Asset Subtitle

Kanishka Uttam Chandani

Meta Tag

Speaker Kanishka Uttam Chandani

Topic Global Health, Health Services & Health Economics

Keywords

immune checkpoint inhibitors

racial disparities

gender disparities

immune-related adverse effects

cancer patients

National Inpatient Sample

socioeconomic factors

insurance coverage

predictive biomarkers

healthcare equity